$1.48
+0.04
(+2.78%)▲
5.41%
Downside
Day's Volatility :6.98%
Upside
1.66%
29.05%
Downside
52 Weeks Volatility :72.15%
Upside
60.74%
Period | Adicet Bio, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 9.63% | 5.1% | 0.0% |
6 Months | -38.08% | 4.9% | 0.0% |
1 Year | -16.85% | 16.6% | 0.0% |
3 Years | -81.15% | 13.2% | -22.3% |
Market Capitalization | 122.0M |
Book Value | $2.85 |
Earnings Per Share (EPS) | -2.59 |
PEG Ratio | 0.82 |
Wall Street Target Price | 9.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -29.3% |
Return On Equity TTM | -57.91% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 25.0M |
EBITDA | -121.5M |
Diluted Eps TTM | -2.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.37 |
EPS Estimate Next Year | -1.52 |
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Next Quarter | -0.37 |
What analysts predicted
Upside of 508.11%
Sell
Neutral
Buy
Adicet Bio, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Adicet Bio, Inc. | 10.45% | -38.08% | -16.85% | -81.15% | -85.04% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Adicet Bio, Inc. | NA | NA | 0.82 | -1.37 | -0.58 | -0.29 | NA | 2.85 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Adicet Bio, Inc. | Buy | $122.0M | -85.04% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Adicet Bio, Inc.
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 54.0%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 150.3%
Orbimed Advisors, LLC
TANG CAPITAL MANAGEMENT LLC
RA Capital Management, LLC
Goldman Sachs Group Inc
Morgan Stanley - Brokerage Accounts
Millennium Management LLC
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v
Organization | Adicet Bio, Inc. |
Employees | 143 |
CEO | Mr. Chen Schor BA, CPA, M.B.A. |
Industry | Distribution Services |
A Spac I Acquisition Corp
$1.48
+2.78%
Keyarch Acquisition Corp
$1.48
+2.78%
Connexa Sports Technologies Inc
$1.48
+2.78%
Us Value Etf
$1.48
+2.78%
First Wave Biopharma Inc
$1.48
+2.78%
Global X Msci Next Emerging
$1.48
+2.78%
Fat Projects Acquisition Corp
$1.48
+2.78%
Capital Link Global Fintech
$1.48
+2.78%
Applied Uv Inc
$1.48
+2.78%